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Abstract. The molecular characterization of tumor samples by multiple omics data sets
of different types or modalities (e.g. gene expression, mutation, CpG methylation) has
become an invaluable source of information for assessing the expected performance
of individual drugs and their combinations. Merging the relevant information from the
omics data modalities provides the statistical basis for determining suitable therapies for
specific cancer patients. Different data modalities may each have their specific struc-
tures that need to be taken into account during inference. In this paper, we assume that
each omics data modality has a low-rank structure with only few relevant features that
affect the prediction and we propose to use a composite local nuclear norm penalization
for learning drug sensitivity. Numerical results show that the composite low-rank struc-
ture can improve the prediction performance compared to using a global low-rank ap-
proach or elastic net regression.
1 Introduction
In recent years, large-scale ex-vivo pharmacological profiling of cancer drugs on a
panel of cancer cell lines, which are well characterised by multiple omics data sets, have
been proposed as a promising route to precision medicine [5, 8, 9, 11]. The omics data
can for example consist of genome-wide measurements of mRNA expression, DNA
copy numbers, DNA single point and other mutations or CpG methylation of cell lines.
These measurements reflect different heterogeneous molecular profiles of the cancer
cell lines with respect to driver effects, intra correlations, measurement scales and back-
ground noise [10]. The response or sensitivity of a cell line to a drug is characterized by
parameters estimated from the dose-response curve, for example by the half maximal
inhibitory concentration (IC50) [7].
Various supervised machine learning methods have been proposed for the problem
of drug response prediction. For example, [6] utilize a multiple kernel learning (MKL)
approach to combine different datasets and explicitly incorporate prior biological infor-
mation. [3] combine a MKL approach with matrix factorization, using the model to
uncover the latent relationships between drug targets and intracellular pathways. Some
other related works can be found in a recent review by [1].
Combining different data sources and prior biological knowledge can clearly help
shed light on the complexities of cancer drug sensitivity prediction. However, most of
the previous approaches based on combined multiple omics data employ a global struc-
ture for parameters inference such as low-rank or sparsity. However, in this application
each data source has its own specific structure that is important for capturing the effects
of drug sensitivity. Borrowing motivation from the recent work [12] in another appli-
cation domain that explores a composite local low-rank structure, we propose to use a
local low-rank model for predicting drug sensitivity with multi-omics data. To the best
of our knowledge, it is the first time a composite local low-rank structure is applied in
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the context drug sensitivity prediction with multi-omics data.
2 Materials and Methods
The pharmacological data Y = {yij} ∈ Rn×q represent the sensitivities of n sam-
ples (e.g., cell lines or patients) to q drugs. We observe the high-dimensional (multi-
omics) data that contain pk features Xk ∈ Rn×pk for k = 1, . . . , K, and in total all
p =
∑K
k=1 pk features are available for n samples across the different data modalities.
HereX = (X1, . . . , XK) ∈ Rn×p and let’s denote the linear model mapping from high-
dimensional covariate data to multivariate responses as
Y =
K∑
k=1
XkBk + E = XB+ E (1)
where B = (B⊤1 , . . . , B
⊤
K)
⊤ ∈ Rp×q is the unknown regression coefficient matrix parti-
tioned corresponding to the predictor groups. The random errors E are assumed to be
zero-mean, where specific correlation structures are examined in the simulation study.
Under the model (1), we assume each omics data set Xk has its own low-rank coef-
ficient matrix Bk. Note that this local low-rank assumption does not necessarily imply
a low-rank structure of the whole coefficient matrix B. We propose to use a composite
nuclear-norm penalization to estimate a local low-rank structure
BˆCLR = arg min
B∈Rp×q
1
2n
‖Y −XB‖22 + λ
K∑
k=1
wk‖Bk‖∗, (2)
where λ > 0 is a tuning parameter and wks are pre-specified weights. Here ‖A‖s =
(
∑
ij |Aij |s)1/s denotes the matrix ℓs-norm and ‖A‖∗ =
∑rank(A)
j=1 σj(A) is the nuclear
norm with σj(·) denoting the jth largest singular value of the enclosed matrix. As
studied in [12], the weights are used to adjust for the dimension and scale differences of
Xks and the choice
wk = σ1(Xk)(
√
q +
√
rank(Xk))/n (3)
balances the penalization of different views and allows us to use only a single tuning
parameter.
Remark 1: Note that problem (2) covers other well-known problems as its special
cases such as:
i) global low-rank structrure, also known as nuclear norm penalized regression:
with p1 = p,K = 1 the penalty in (2) becomes the nuclear norm penalty of the
whole parameter matrixB.
ii) multi-task learning: with pk = 1, p = K, (2) becomes a special case of multi-task
learning that all the tasks share the same set of features and samples.
Remark 2: Some theoretical results of the composite local low-rank estimator (2)
have been laid out in [12] for a specific case where E has i.i.d Gaussian entries. More
specifically, non-asymptotic bounds for estimation and prediction are given in the The-
orem 1 and Theorem 2 in [12].
3 Numerical study
In this section, we conduct simulation studies to examine the efficacy of the proposed
composite local low-rank method. The R code to reproduce the results is available at
https://github.com/zhizuio/LowRankLearning.
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3.1 Simulation setups and details
Using the dimensionalities: q = 24, n = 90, K = 2, p1 = p2 = 100, the data are
simulated as in linear model (1), where X = [X1, X2]. Each Xk(k = 1, 2) is generated
from a multivariate normal distribution with mean 0 and covariance matrix ΣX . The
covariance matrix ΣX has the diagonal values equal to 1 and all off-diagonal elements
equal to ρX ≥ 0. To take into account the correlation between the drugs, we simulate
the noise E from a multivariate normal distribution with mean 0 and covariance matrix
Σǫ. The covariance matrix Σǫ has the diagonal values equal to 1 and all off-diagonal
elements equal to ρǫ ≥ 0.
We vary different correlation setups in omics dataX and the drugs as follows:
(a). fix ρX = 0 and vary ρǫ as 0.0; 0.3; 0.6,
(b). fix ρǫ = 0 and vary ρX as 0.3; 0.6; 0.9.
Then, for each of the above setups, we consider various settings for the true coefficient
matrix B = (B⊤1 , B
⊤
2 ) as:
S1: eachBk, k = 1, 2 is a low-rank matrix with rank(B1) = 4, rank(B2) = 6which is
generated as Bk = Lrank(Bk)R
⊤
rank(Bk)
with the entries of Lrank(Bk) ∈ Rpk×rank(Bk)
and Rrank(Bk) ∈ Rq×rank(Bk) both generated fromN (0, 1).
S2: B1 is low-rank as in S1 and B2 is a sparse matrix where 50% of the elements are
non-zero and simulated from N (0, 1).
S3: global low-rank, the whole matrix B is a rank-2 matrix.
S4: global sparsity, the whole matrix B is sparse where 20% of the elements are non-
zero and simulated from N (0, 1).
Table 1: MSPE with fixed ρX = 0 and ρǫ is varied. The composite low-rank (CLR) method returns the
smallest prediction errors. In general, the prediction errors for the 3 methods are increasing when the
correlation between drugs increase.
ρǫ = 0 ρǫ = 0.3 ρǫ = 0.6
CLR GLR Enet CLR GLR Enet CLR GLR Enet
setting S1 (local low-rank) 0.011 0.517 5.111 0.018 0.727 9.172 0.025 1.659 9.755
setting S2 (low-rank, sparse) 0.011 0.056 3.286 0.018 0.066 3.834 0.025 0.083 4.318
setting S3 (global low-rank) 0.011 0.899 12.81 0.018 1.228 21.45 0.025 2.212 20.00
setting S4 (global sparsity) 0.011 0.023 0.237 0.018 0.076 0.321 0.025 0.068 0.695
Table 2: MSEE with fixed ρX = 0 and ρǫ is varied. The composite low-rank (CLR) returns the smallest
error when there is local low-rank structrure in the data, while the reduced-rank regression (GLR) returns
the smallest error when there is a global structrure.
ρǫ = 0 ρǫ = 0.3 ρǫ = 0.6
CLR GLR Enet CLR GLR Enet CLR GLR Enet
setting S1 (local low-rank) 1.931 2.753 7.788 1.949 2.790 7.271 1.899 2.744 7.844
setting S2 (low-rank, sparse) 0.880 1.254 3.486 0.872 1.234 3.389 0.895 1.278 3.531
setting S3 (global low-rank) 1.133 1.121 3.047 1.173 1.142 3.061 1.177 1.109 2.868
setting S4 (global sparsity) 0.121 0.114 0.319 0.125 0.117 0.328 0.131 0.122 0.322
We compare the composite local low-rank estimator (CLR) in (2) with a global low-
rank estimator (GLR) for the reduced-rank regression,
BˆGLR = arg min
B∈Rp×q
1
2n
‖Y −XB‖22, s.t rank(B) ≤ r
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and the elastic-net (sparsity-inducing) estimator (Enet)
Bˆenet = arg min
B∈Rp×q
1
2n
‖Y −XB‖22 + λ(α‖B‖1 + 0.5(1− α)‖B‖22).
We use an implementation of the reduced-rank regression from R package ’rrpack’1
where the rank is chosen by cross-validation. For the elastic-net, we use the R package
’glmnet’2 with λ chosen by 10-folds cross-validation and α = 0.2.
The evalutions are done by using the mean squared estimation error (MSEE) and the
mean squared prediction error (MSPE)
MSEE :=
1
pq
‖Bˆ −B‖22, MSPE :=
1
nq
‖Y −XBˆ‖22.
Note that in real-world applications, where the trueB is not known, we can only access
the prediction errors. We repeat each experiment setting 30 times and report the mean
of the outputs.
3.2 Numerical results
A first conclusion from the numerical results is that the proposed composite local
low-rank (CLR) method has the smallest prediction error. This can be seen from the
Table 1 and Table 3. In term of estimation error, the reduced-rank regression (global
low-rank method, GLR) seems to be better and also more robust to the correlation be-
tween the drugs (Table 2) and between the covariates (Table 4). On the other hand, the
Elastic-Net neither works well for estimation nor for prediction.
Regarding the prediction error, besides the fact that the CLR method returns the
smallest prediction errors, it is also robust to the correlation between the covariates (the
omics data) as in Table 3. This can be easily seen as the composite local low-rank
method does take into account the local structure of each omics data. On the other
hand, as the correlation between the drugs increases, the prediction errors of the CLR
also increase. Therefore, it would be nice to incorporate the drugs correlation into the
preposed prediction method, this idea has been studied in a different model in [14].
On the estimation error, the global low-rank (GLR) method works better than CLR
and Enet, see Table 2 and Table 4. In particular, the proposed composite local low-rank
(CLR) method returns very high estimation errors in all simulation settings (except S4)
when the correlation between the covariates increases in Table 4. This could be due to
the weights wk in (3) being calculated based on the theoretical study for independent
and identical distributed errors, and a restricted eigenvalue condition onX , see [12].
4 Real data analysis: GDSC data
To test our approach on a real dataset, we use data from a large-scale pharmacoge-
nomic study, the Genomics of Drug Sensitivity in Cancer (CDSC) [13], made available
online3 by Garnett et al. [8]. The dataset consists of drug sensitivity data (IC50) for a
large panel of cancer drugs screened on multiple cell lines, in addition to various omics
measurements from the cancer cell lines.
We select a subset of the data, consisting of 97 screened drugs and 498 human cancer
cell lines from 13 cancer tissue types, such that the response matrix Y ∈ R498×97 is
fully observed. For each cell line, they measured the mutation status for a panel of
known cancer genes, and genome-wide copy number variation and gene expression.
For data preprocessing and feature selection, we follow the procedure by [14], which
results in preselecting 68 binary mutation features (X1 ∈ R498×68), 426 integer copy
1https://cran.r-project.org/package=rrpack
2https://cran.r-project.org/package=glmnet
3ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/release-5.0/
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Table 3: MSPE with fixed ρǫ = 0 and ρX is varied. The composite low-rank (CLR) method returns the
smallest prediction errors.
ρX = 0.3 ρX = 0.6 ρX = 0.9
CLR GLR Enet CLR GLR Enet CLR GLR Enet
setting S1 (local low-rank) 0.011 0.524 20.40 0.012 0.525 23.01 0.011 0.521 136.5
setting S2 (low-rank, sparse) 0.011 0.041 10.10 0.011 0.087 12.00 0.011 0.130 30.77
setting S3 (global low-rank) 0.012 0.895 23.34 0.011 0.893 26.29 0.011 0.891 99.65
setting S4 (global sparsity) 0.012 0.062 0.272 0.011 0.087 0.451 0.012 0.298 1.667
Table 4: MSEE with fixed ρǫ = 0 and ρX is varied. Overall, the reduced-rank regression (GLR) returns
the smallest error.
ρX = 0.3 ρX = 0.6 ρX = 0.9
CLR GLR Enet CLR GLR Enet CLR GLR Enet
setting S1 (local low-rank) 2.165 2.755 7.640 4.691 2.752 7.855 14.60 2.726 7.692
setting S2 (low-rank, sparse) 1.153 1.298 3.581 1.828 1.243 3.507 5.447 1.186 3.266
setting S3 (global low-rank) 1.213 1.131 3.014 1.235 1.054 2.860 4.225 1.137 3.167
setting S4 (global sparsity) 0.121 0.112 0.331 0.120 0.112 0.331 0.119 0.112 0.335
number features (X2 ∈ R498×426) and 2602 continuous gene expression features (X3 ∈
R
498×2602), respectively, and the drug sensitivity being measured as log IC50. Note that,
we did not consider 13 cancer tissue indicators in our analysis as it is non-omics data.
The CLR method has the similar predictive ability as GLR (with high-rank) for the
GDSC data set. The estimated ranks of each omics data source B1 ∈ R2602×97, B2 ∈
R
426×97, B2 ∈ R68×97 from the composite local low-rank model are 97, 54 and 61 re-
spectively. For reduced-rank regression (GLR), we fit model with maximum rank to
be 50 and the best selected rank is 50. Thus it is clear that there is no global low-rank
structure in this real data. For elastic net, 99% of the coefficient is estimated to be zero.
Table 5: MSPE with real data.
CLR GLR (rank-50) Enet
real data 0.3340 0.3350 0.7475
5 Discussion and Conclusion
In this paper, we have studied the problem of drug sensitivity prediction with multi-
omics data. Under the assumption that each omics data modality affects the drug sen-
sitivity prediction only through a few latent features (low-rankness), we propose to use
a composite local low-rank model that takes into account this local structure. Our nu-
merical results illustrate beneficial performance regarding the prediction errors of the
proposed method compared to global methods, such as reduced-rank regression and
elastic net.
This paper represents an initial take on the drug prediction based on local low-rank
structures. There are some clear limitations in our approach, such as: (i) incorporating
correlations between drugs and the heterogeneity of multi-omics data, as in [14], into
our model would help to make our method more robust; (ii) incorporating other local
structure rather than low-rankness, could help our method to become more flexible;
(iii) extending the proposed method by including full-rank “mandatory” non-omics data
sources (e.g clinical variables). These problems open further venues of research in this
area in the future.
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